I would also say that there isn’t really VC for ambitious biotech. The way that VC works in biotech is that it’s mostly about funding the professor and his 12 postdocs that invented something (call it X) and then they spin out of a university and you fund the company doing X. That’s basically the main model. It doesn’t leave a lot of room for biology projects that aren’t spin outs. “Techbio” has been a recent improvement but it seems to be a lot of software startups? I’m not sure.
On longevity, I should add that I think more people working on ending aging would be good. In the past 5-10 years a lot more companies and funds have formed around longevity so that’s very exciting to see. But admittedly we don’t have an over-abundance of people working on extreme aging interventions; maybe a few million more people would be good to work on that problem?
I would also say that there isn’t really VC for ambitious biotech. The way that VC works in biotech is that it’s mostly about funding the professor and his 12 postdocs that invented something (call it X) and then they spin out of a university and you fund the company doing X. That’s basically the main model. It doesn’t leave a lot of room for biology projects that aren’t spin outs. “Techbio” has been a recent improvement but it seems to be a lot of software startups? I’m not sure.
On longevity, I should add that I think more people working on ending aging would be good. In the past 5-10 years a lot more companies and funds have formed around longevity so that’s very exciting to see. But admittedly we don’t have an over-abundance of people working on extreme aging interventions; maybe a few million more people would be good to work on that problem?